News in English
Tivdak (tisotumab vedotin) has received approval from the Japanese Ministry of Health. This means that the treatment is the first and only antibody-drug conjugate (ADC) to be approved for people living with cervical cancer in Japan.
The approval is based on data from a randomized study showing that the treatment reduces the risk of death by 30 procent compared to chemotherapy. The median survival was 11.5 months for patients who received Tivdak compared to 9.5 months for those who received chemotherapy.